论文部分内容阅读
目的:探讨奥沙利铂联合5-Fu/LV的新辅助化疗在中低位直肠癌中的疗效。方法:2003~2005年收治的57例估计可切除的中低位直肠癌患者,分为实验组(23例)和对照组(34例),实验组于术前1周行奥沙利铂联合5-Fu/LV的方案化疗1疗程,奥沙利铂,130mg/m2(体表面积),2h静脉滴注,第一天用;亚叶酸钙,200mg/m2,2h静脉滴注,连用5d;5-Fu,300mg/m2,4~6h静脉泵入,连用5d。对照组不作任何放化疗。结果:实验组78·26%(18/23)的患者肿瘤体积缩小,变软。实验组手术根治率、保肛率显著高于对照组(P<0·05),淋巴结转移率则显著低于对照组(P<0·05)。结论:术前奥沙利铂联合5-Fu/LV的新辅助化疗可显著提高中低位直肠癌的根治率和保肛率,降低淋巴结转移率。
Objective: To investigate the efficacy of oxaliplatin combined with 5-Fu / LV neoadjuvant chemotherapy in low and middle rectal cancer. Methods: Fifty-seven patients with resectable low or middle rectal cancer were enrolled in this study. They were divided into experimental group (23 cases) and control group (34 cases). The experimental group received oxaliplatin combined with 5 --Fu / LV chemotherapy 1 course of treatment, oxaliplatin, 130mg / m2 (body surface area), 2h intravenous drip, the first day; leucovorin, 200mg / m2, 2h intravenous infusion, -Fu, 300mg / m2, 4 ~ 6h intravenous infusion, once every 5d. The control group did not make any radiotherapy and chemotherapy. Results: In the experimental group, 78.26% (18/23) of the patients had the tumor volume reduced and softened. The cure rate and anal sphincter rate in the experimental group were significantly higher than those in the control group (P <0.05). The lymph node metastasis rate in the experimental group was significantly lower than that in the control group (P <0.05). Conclusion: The preoperative oxaliplatin combined with 5-Fu / LV neoadjuvant chemotherapy can significantly improve the cure rate and anal sphincter rate in low and middle rectal cancer, reduce the rate of lymph node metastasis.